Attached files
| file | filename |
|---|---|
| EX-10.68 - EX-10.68 - NOVELION THERAPEUTICS INC. | d543393dex1068.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 24, 2012
QLT Inc.
(Exact Name of Registrant as specified in its charter)
| British Columbia, Canada | 000-17082 | N/A | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
887 Great Northern Way, Suite 101, Vancouver, B.C.
Canada, V5T 4T5
(Address of principal executive offices)
Registrant’s telephone number, including area code: (604) 707-7000
Not Applicable
(Registrant’s name or former address, if change since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory Note
On December 31, 2012, QLT Inc. (the “Company”) filed a Current Report on Form 8-K dated December 24, 2012 (the “Original 8-K”) with the Securities and Exchange Commission (“SEC”). This Amendment No. 1 to the Original 8-K is being filed solely for the purpose of re-filing Exhibit 10.68 to the Original 8-K (the “Exhibit”) pursuant to comments received from the Staff of the SEC on the Company’s application for confidential treatment of certain information that was redacted from the Exhibit. All other disclosures contained in the Original 8-K remain unchanged.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Number |
Description | |
| 10.68* | Option Agreement between the Company and Mati Therapeutics Inc., dated December 24, 2012 | |
| * | Confidential treatment has been requested as to certain portions of this Exhibit. Such portions have been omitted and filed separately with the Securities and Exchange Commission. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| QLT INC. | ||
| By: | /s/ Sukhi Jagpal | |
| Name: | Sukhi Jagpal | |
| Title: | Chief Financial Officer | |
Date: May 23, 2013